October 27 & 28, 2020

Speakers

After a European PhD on the humanization of the N-glycosylation of recombinant monoclonal antibodies produced in transgenic plants, Dr Muriel Bardor spent two years as a post-doctoral research fellow at the University of California San Diego, USA. There, she worked on the sialic acid biology in mammalian cells in Pr Ajit Varki’s glycobiology lab. In 2003, she has been appointed as an Associate professor at the University of Rouen in plant glycobiology. She performed a two years oversea period working from 2010 to 2012 as the Head of the Bioprocessing Technology Institute Analytics group in Singapore where she developed analytical methodologies to characterize finely biopharmaceuticals produced in Chinese Hamster Ovary Cells. She is currently professor at the University of Rouen Normandie, Glyco-MEV laboratory, Carnot I2C in charge of a research project dedicated to the understanding of the glycosylation pathways in microalgae and demonstrated that microalgae could represent interesting alternative expression system for the production of biopharmaceuticals such as monoclonal antibodies.

Pr BARDOR Muriel has published more than 60 peer reviewed research articles, 24 chapters, reviews and others writings, 7 patents, given more than 30 invited talks and seminars and has developed a large network of national and international collaborations. She led national and international scientific projects (e.g. ANR KBBE, IUF, H2020…), coordinated research collaborative agreements with private institutions (MEDICAGO Inc., Agilent Technologies, SAMABRIVA…). Bonus awards for PhD supervision and excellence in science (PEDR) have been attributed to her since 2006. In 2014, she has been appointed as a junior member of the “Institut Universitaire de France” (IUF) thus reflecting the excellence of the science that she is leading.

Biochemist with a PhD in Biotechnology from INA-PG/ AgroParisTech, Thanos Beopoulos worked for several years in the metabolic engineering of yeast and bacteria for the production of oleochemicals, pharmaceuticals and antibiotics. During these years he worked at the genetic engineering department of CNRS Paris-Grignon and at INRA, MICALIS. After a short period at MITs chemical engineering department, he worked with AAK Sweden on the microbial conversion of Shea processing side products to value added oleochemicals.

From 2016, he joined Bio-Modeling Systems as an integrative biologist where he develops predictive biological models and identifies potential treatments for untreated human pathologies such as (auto) immune, neurological, metabolic and cancer related diseases.

Sandra Castang obtained her PhD in Molecular Microbiology and Structural Biology in 2006 from University of Claude Bernard Lyon I. Her PhD work in the Unit of Microbiology, Adaptation and Pathogeny consisted in studying quorum sensing regulators of the plant pathogen Erwinia chrysanthemi in order to develop alternative to antibiotics. Prior to joining DEINOVE, she worked as a Postdoctoral Research Fellow in the Infectious Diseases department of Children’s Hospital, Harvard University, in Boston where she worked, on coordinate regulation of virulence genes expression in the opportunistic bacterium Pseudomonas aeruginosa. She joined DEINOVE in 2011 as a Research Scientist in green chemistry. Since 2017, she leads the Carotenoids Program of DEINOVE, from Deinococcus strain metabolic engineering, upstream and downstream processes development to industrial scaling up and commercialization.

32 years experience in Pharma R&D

Head of Protein Science & Technology and Deputy Head Biologics Research Vitry,Sanofi

Between 2012 and 2014 global Head of Protein Biotherapeutics. Previously Head of Protein Production during 12 years in Aventis and Sanofi-Aventis (2000 –2012). Group Leader in Biotechnology, Hoechst Marion Roussel, 1988 –2000, (12 years). PhD in 1988 in Cellular and Molecular Biology (University Paris VI, France): Purification, biochemical and immunological characterization of human teeth collagenase, in Protein Chemistry Lab Institut Pasteur of Paris.

Main expertises in R&D on expression and purification/characterization/developability of recombinant proteins and antibodies, Biologics, for Medicinal Chemistry and Biotherapeutics projects for all kind of uses (screening, crystallography, IHC, PK-PD, in vitro and in vivo studies…). Purification of proteins, from mg scale to several grams (DSP). Support to Medicinal Chemistry projects, and development of purification processes for Biologics. Metalloproteinases.  Previously project leader of Cardiovascular and Anti-Infective projects.

Lorie Hamelin, senior researcher at the Federal University of Toulouse, is a laureate of the French presidential climate call “Make our planet great again” (Project Cambioscop), and currently heads a research team of 2 postdocs and 5 PhDs. Her research lies at the crossroads of bioeconomy, circular economy & renewable energy systems, focusing on the environmental- and cost- performance of strategies to transit towards a low fossil carbon economy, at the national or regional scales. In other words, Dr. Hamelin strives to re-think how we supply food, energy and chemicals to the World, as well as how we manage waste. Life Cycle Assessment, Energy System Analysis and Geographical Information Systems are the key analytical tools she applies and develop in her research. Prior to her research in France, Dr. Hamelin worked as an assistant professor in the Centre for Life cycle Engineering at the University of Southern Denmark, and has been recruited in the framework of the European ERA Chair Programme to work as a senior scientist on bioeconomy research in Poland. She further founded her own consulting company (Hamelinlab) in France. Dr. Hamelin currently serves as an expert in the International Scientific Reference Group of the Swedish Biogas research Centre, co-lead a Sectorial Working Group (SWG) of the Ecosystem Services Partnership (ESP) network on circular bioeconomy and is member of the European Energy Research Alliance. Since 2010, Dr. Hamelin participated and served as a WP leader in 10 European bioeconomy-related projects.

Philippe was graduated in 1995 with a Ph.D. in Biochemistry from the University of Liège in Belgium. He studied at the Centre for Protein Engineering the resistance mechanisms developed by bacteria against β-lactam antibiotics. He acquired extensive expertise in molecular biology, fermentation, protein purification and characterization.

After an additional year at the University of Liège where he studied thermodynamical and kinetic properties of enzymes produced by extremophile microorganisms, Philippe began to work in 1996 as Scientist at the Unit of Bioengineering at University of Louvain-la-Neuve in the field of environmental biotechnology.

In 1999, he became R&D Manager at Realco, a SME based in Louvain-la-Neuve, a company active in the development of enzyme and microorganism based products for household and industry applications, including wastewater treatment and farming applications.

Philippe joined Eurogentec in 2002 first as Project Leader in the Process Transfer & Development department. In 2007, he managed that department whose activities were the development of fermentation and purification processes including the development of the analytical tools for the monitoring of the different upstream and downstream steps and the characterization of the final product.

In April 2014, Philippe co-founded with two Partners, Marc Daukandt and Christian Rodriguez, the company called Xpress Biologics, a new Contract Development & Manufacturing Organization based in Liège, dedicated to the production of biomolecules including recombinant proteins, antibody fragments and plasmid DNA, for therapeutic and vaccine applications in the fields of human and veterinary healthcare as well as in diagnostic. As Chief Scientific Director, he is implied in the technical and scientific support of all the R&D external and internal projects as well as in the business development.

Leonardo Magneschi obtained a Ph.D. in Plant and Microbial Biotechnology from Scuola Superiore Sant’Anna, Pisa (Italy) in 2011.  After his Ph.D. he moved to Muenster (Germany) where he was awarded an Alexander von Humboldt postdoctoral fellowship to investigate the molecular basis of abiotic stress responses and biofuel production in single cell algae (2011-2014).  Leonardo left academia in 2014 and joined a two-year “TOTAL New Energies” industrial project in collaboration with the CEA Grenoble (France; 2014-2016), where he developed cutting edge molecular tools for metabolic engineering and genome editing of non-model photosynthetic microbes.  Throughout his career at Ingenza Ltd, which started in 2016, Leonardo has been directly involved in the design and construction of strains for a number of commercial customer projects, ranging from pharma, biofuels and renewable materials, thus acquiring first-hand experience in genetic engineering of both prokaryotic and eukaryotic hosts.  Leonardo has published 17 papers in international peer-reviewed scientific journals and was recently granted inventorship on two international patents.  Two additional patents were submitted in 2020.

Jean-Baptiste Penigault holds a PhD. In Evolutionary and Developmental Biology From University Paris Diderot. Shortly after his PhD defense he jumped in the industry as a sales specialist in capital equipment in 2010 and focused on disruptive technologies for the Life science industry and academic research. Jean-Baptiste is currently Account Manager (Southern Europe) at Berkeley Lights Inc.

Contenu d’accordéon

Current position

Section Head CMC Pharmaceutical development & technology, Host Creation and Upstream Development

Company Name

Ablynx a Sanofi company

Employment Duration

14 yrs

Activities

  • Project management and line-management responsibilities wrt Host creation & upstream development using Pichia pastoris and E.coli and internal projects from discovery to clinical development.

Past position (before 2006)

  • Studied at the University of Ghent and worked at the Department for Molecular and Biomedical Research (DMBR), Faculty of Science, Flanders Institute for Biotechnology (VIB) – Ghent University, Belgium till 2006 as postdoctoral researcher in area of immunology and inflammation.

Prof. Wim Soetaert holds a degree in chemical and biochemical engineering and did a PhD in bioengineering at Ghent University.

Prof. Wim Soetaert currently heads the Centre of Expertise for Industrial Biotechnology and Biocatalysis (InBio.be) at Ghent University, Faculty of BioScience Engineering. InBio is active in the areas of industrial biotechnology, biocatalysis, fermentation science and engineering and counts about 40 people. www.inbio.be

He is the founder and chairman of Ghent Bio-Economy Valley, a public private partnership to promote the development of biobased activities in the Ghent area in Belgium. Since its creation in 2005, Ghent Bio-Energy Valley has quickly grown into one of the main growth centers for the biobased economy in Europe, with over 500 Million euros already invested in the port of Ghent. www.gbev.org

Prof. Wim Soetaert is also the director of the Bio Base Europe Pilot Plant, an open innovation Pilot Plant for biobased products and processes based in Ghent. Within the framework of an Interreg project, over 21 Million euros have been invested in Bio Base Europe sofar. www.bbeu.org

Prof. Wim Soetaert is the founder and executive chairman of Inbiose, a spin-off company of Ghent University that is producing speciality carbohydrates through industrial biotechnology. www.inbiose.com

During his earlier career, Wim Soetaert has worked as a research director in Germany and France, for the sugar group Pfeifer & Langen and the wheat processing company Chamtor.

Lars Stöckl is a leading scientist at Glycotope GmbH since 2005. As cell and protein biochemist he first was responsible for the development of novel GlycoExpress cell lines which resulted in MabExpress, a cell line glycoengineered for the production of higher active antibodies. Since 2007 he is project manager of one of Glycotope’s most advanced pipeline project FSH-GEX and since January 2020 he is heading the service division of Glycotope.

Before the appointment at Glycotope he studied Chemistry at the Technical University of Munich and gained experience in the field of cell line engineering and protein chemistry during his PhD and Postdoctoral fellowship at the Robert Koch-Institute /Berlin, the Charite / Berlin and the Breakthrough Breast Cancer Research / London.

Moritz von Stosch leads the Process Systems Biology and Engineering Center of Excellence, as Senior Manager at Technical R&D of GSK Biologicals, Belgium. He co-founded several companies for faster Insilico based process development and he serves as an Advisory board member for two software and service companies as well as for two academic institutions. Dr. von Stosch is a process systems engineer by education with a Diplom in Chemical Engineering from the RWTH-Aachen University and PhD in Biochemical Engineering from the University of Porto. Before joining GSK, he worked as a Lecturer at the School of Chemical Engineering and Advanced Materials at Newcastle University, where his research focused on the development of novel hybrid modeling methods and their application to enable more efficient process operation/design.